Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort
Abstract Neuroendocrine neoplasms are known to have heterogeneous biological behavior. G3 neuroendocrine tumours (NET G3) are characterized by well-differentiated morphology and Ki67 > 20%. The prognosis of this disease is understood to be intermediate between NET G2 and neuroendocrine carcinoma...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9356d6a6d0ae41e293f5a2588faaf195 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9356d6a6d0ae41e293f5a2588faaf195 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9356d6a6d0ae41e293f5a2588faaf1952021-12-02T17:19:16ZWell-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort10.1038/s41598-021-97247-x2045-2322https://doaj.org/article/9356d6a6d0ae41e293f5a2588faaf1952021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97247-xhttps://doaj.org/toc/2045-2322Abstract Neuroendocrine neoplasms are known to have heterogeneous biological behavior. G3 neuroendocrine tumours (NET G3) are characterized by well-differentiated morphology and Ki67 > 20%. The prognosis of this disease is understood to be intermediate between NET G2 and neuroendocrine carcinoma (NEC). Clinical management of NET G3 is challenging due to limited data to inform treatment strategies. We describe clinical characteristics, treatment, and outcomes in a large single centre cohort of patients with gastroenteropancreatic NET G3. Data was reviewed from 26 cases managed at Queen Elizabeth Hospital, Birmingham, UK, from 2012 to 2019. Most commonly the site of the primary tumour was unknown and majority of cases with identifiable primaries originated in the GI tract. Majority of cases demonstrated somatostatin receptor avidity. Median Ki67 was 30%, and most cases had stage IV disease at diagnosis. Treatment options included surgery, somatostatin analogs (SSA), and chemotherapy with either platinum-based or temozolomide-based regimens. Estimated progression free survival was 4 months following initiation of SSA and 3 months following initiation of chemotherapy. Disease control was observed following treatment in 5/11 patients treated with chemotherapy. Estimated median survival was 19 months; estimated 1 year survival was 60% and estimated 2 year survival was 13%. NET G3 is a heterogeneous group of tumours and patients which commonly have advanced disease at presentation. Prognosis is typically poor, though select cases may respond to treatment with SSA and/or chemotherapy. Further study is needed to compare efficacy of different treatment strategies for this disease.K. LithgowH. VenkataramanS. HughesH. ShahJ. Kemp-BlakeS. VickrageS. SmithS. HumphriesM. ElshafieP. TaniereS. Diaz-CanoB. V. M. DasariM. AlmondS. FordJ. AyukS. ShettyT. ShahI. GehNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q K. Lithgow H. Venkataraman S. Hughes H. Shah J. Kemp-Blake S. Vickrage S. Smith S. Humphries M. Elshafie P. Taniere S. Diaz-Cano B. V. M. Dasari M. Almond S. Ford J. Ayuk S. Shetty T. Shah I. Geh Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort |
| description |
Abstract Neuroendocrine neoplasms are known to have heterogeneous biological behavior. G3 neuroendocrine tumours (NET G3) are characterized by well-differentiated morphology and Ki67 > 20%. The prognosis of this disease is understood to be intermediate between NET G2 and neuroendocrine carcinoma (NEC). Clinical management of NET G3 is challenging due to limited data to inform treatment strategies. We describe clinical characteristics, treatment, and outcomes in a large single centre cohort of patients with gastroenteropancreatic NET G3. Data was reviewed from 26 cases managed at Queen Elizabeth Hospital, Birmingham, UK, from 2012 to 2019. Most commonly the site of the primary tumour was unknown and majority of cases with identifiable primaries originated in the GI tract. Majority of cases demonstrated somatostatin receptor avidity. Median Ki67 was 30%, and most cases had stage IV disease at diagnosis. Treatment options included surgery, somatostatin analogs (SSA), and chemotherapy with either platinum-based or temozolomide-based regimens. Estimated progression free survival was 4 months following initiation of SSA and 3 months following initiation of chemotherapy. Disease control was observed following treatment in 5/11 patients treated with chemotherapy. Estimated median survival was 19 months; estimated 1 year survival was 60% and estimated 2 year survival was 13%. NET G3 is a heterogeneous group of tumours and patients which commonly have advanced disease at presentation. Prognosis is typically poor, though select cases may respond to treatment with SSA and/or chemotherapy. Further study is needed to compare efficacy of different treatment strategies for this disease. |
| format |
article |
| author |
K. Lithgow H. Venkataraman S. Hughes H. Shah J. Kemp-Blake S. Vickrage S. Smith S. Humphries M. Elshafie P. Taniere S. Diaz-Cano B. V. M. Dasari M. Almond S. Ford J. Ayuk S. Shetty T. Shah I. Geh |
| author_facet |
K. Lithgow H. Venkataraman S. Hughes H. Shah J. Kemp-Blake S. Vickrage S. Smith S. Humphries M. Elshafie P. Taniere S. Diaz-Cano B. V. M. Dasari M. Almond S. Ford J. Ayuk S. Shetty T. Shah I. Geh |
| author_sort |
K. Lithgow |
| title |
Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort |
| title_short |
Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort |
| title_full |
Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort |
| title_fullStr |
Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort |
| title_full_unstemmed |
Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort |
| title_sort |
well-differentiated gastroenteropancreatic g3 net: findings from a large single centre cohort |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/9356d6a6d0ae41e293f5a2588faaf195 |
| work_keys_str_mv |
AT klithgow welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort AT hvenkataraman welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort AT shughes welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort AT hshah welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort AT jkempblake welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort AT svickrage welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort AT ssmith welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort AT shumphries welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort AT melshafie welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort AT ptaniere welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort AT sdiazcano welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort AT bvmdasari welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort AT malmond welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort AT sford welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort AT jayuk welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort AT sshetty welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort AT tshah welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort AT igeh welldifferentiatedgastroenteropancreaticg3netfindingsfromalargesinglecentrecohort |
| _version_ |
1718381039255027712 |